Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Shuhang Wang"'
Publikováno v:
Journal of the National Cancer Center, Vol 4, Iss 2, Pp 93-96 (2024)
Externí odkaz:
https://doaj.org/article/9fba252b38ae4a6fa57b2f121a9056d1
Autor:
Ning Li, Jian Li, Liang Zhao, Fan Zhang, Wei Guo, Shugeng Gao, Shuhang Wang, Fang Lv, Kang Shao, Qi Xue, Bin Qiu, Bolun Zhou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Background Neoadjuvant anti-programmed cell death protein-1 (PD-1) therapy exhibits potential in treating resectable non-small cell lung cancer (NSCLC). Previously, we have reported the 3-year clinical outcomes of this trial, implying the effectivene
Externí odkaz:
https://doaj.org/article/cdcf1d2a084046878b61a77a23aaf64b
Autor:
Qian Zhang, Xiuli Tao, Pei Yuan, Zewei Zhang, Jianming Ying, Lei Guo, Ning Li, Shuhang Wang, Jing Li, Ying Liu, Wei Guo, Shijun Zhao, Ning Wu
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 20864-20877 (2023)
Abstract Purpose To investigate the correlations between metabolic parameters (MPs) of 18F‐fluorodeoxyglucose (FDG) uptake on positron emission tomography/computed tomography (PET/CT), serum tumor markers (STMs), and tumor mutational burden (TMB) i
Externí odkaz:
https://doaj.org/article/3c481717169c488ca2671e2293cbee2f
Autor:
Huiyao Huang, Jingting Du, Xinyu Meng, Dawei Wu, Yue Yu, Shuhang Wang, Lili Wang, Wenya Wang, Yu Tang, Ning Li
Publikováno v:
Journal of the National Cancer Center, Vol 3, Iss 2, Pp 129-134 (2023)
Objective: To deliver a comprehensive picture of the landscape and changing trend of trials and approvals on targeted anticancer drugs in China from 2012 to 2021. Methods: Trials, investigated products, and listed drugs were acquired from national da
Externí odkaz:
https://doaj.org/article/853ac06aff5f4295bd4c62e9ae679409
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/eecbb4aaf7d14688b9b634575fe5cf95
Autor:
Ning Li, William L Redmond, Brendan Curti, Shuhang Wang, Herui Yao, Erwei Song, Henry Yu, Giorgio Massimini, Ming-Hong Hu, Rongliang Lou, Wanping Geng, Sanlong Wang, Meiling Zhang, Rongchu Chen, Baotian Qin, John Mao, Shaoshan Wang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7b531028babd4a6d95e0a4b089285ad9
Publikováno v:
Molecular Therapy: Oncolytics, Vol 29, Iss , Pp 125-126 (2023)
Externí odkaz:
https://doaj.org/article/0b05bdda50b24f68a347f874ff90bd2f
Autor:
Shuhang Wang, Yuqi Yang, Peiwen Ma, Huiyao Huang, Qiyu Tang, Huilei Miao, Yuan Fang, Ning Jiang, Yandong Li, Qi Zhu, Wei Tao, Yan Zha, Ning Li
Publikováno v:
Molecular Therapy: Oncolytics, Vol 24, Iss , Pp 799-813 (2022)
Tumor-associated macrophages (TAMs) exert integrated effects in all aspects of tumor progression, including tumor cell proliferation, angiogenesis, invasion, and metastasis. Recently, considerable preclinical and clinical trials have demonstrated tha
Externí odkaz:
https://doaj.org/article/5916967ceeb548f4917300a56f89afbe
Autor:
Dawei Wu, Huiyao Huang, Minghui Zhang, Ziwei Li, Shuhang Wang, Yue Yu, Yuan Fang, Ning Jiang, Huilei Miao, Peiwen Ma, Yu Tang, Ning Li
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-4 (2022)
Abstract The neoadjuvant and adjuvant anti-PD-1/PD-L1 treatment has been increasingly noticed. To summarize the global landscape of these clinical trials will provide essential data for all the stakeholders of drug development. Based on the Trialtrov
Externí odkaz:
https://doaj.org/article/11990d94452e40599aebebaa00007503
Autor:
Shuhang Wang, Pei Yuan, Beibei Mao, Ning Li, Jianming Ying, Xiuli Tao, Wei Tang, Lei Zhang, Xiao Geng, Fan Zhang, Qi Xue, Lijia Wu, Henghui Zhang, Shugeng Gao, Jie He
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-8 (2022)
Abstract Several clinical trials have shown the safety and effectiveness of PD-1/PD-L1 inhibitors in neoadjuvant therapy in resectable non-small cell lung cancer (NSCLC). However, 18–83% patients can benefit from it. In this study, we aimed to asse
Externí odkaz:
https://doaj.org/article/5bc25900f6024bea9b9d2581dfdd2d60